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Abstract
Measurement of telomerase activity in clinically obtained tumor samples
may provide important information for use as both a diagnostic marker
and a prognostic indicator for patient outcome. In order to evaluate
telomerase activity in tumor tissue without radiolabeling the product, we
developed a simple telomeric repeat amplification protocol-silver-stain-
ing assay that is less time-consuming, is safe and requires minimal
equipment. In addition, we determined the sensitivity of the silver-
staining method by using extracts of telomerase-positive thyroid carcino-
ma cell lines which were serially diluted from 5,000 to 10 cells. Telomer-
ase activity was also assayed in 19 thyroid tumors, 2 normal controls and
27 bone marrow aspirates. The results indicate that the technique permits
the detection of telomerase activity from 5000 to as few as 10 cells. We
propose that it could be immediately applicable in many laboratories due
to the minimal amount of equipment required.
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The measurement of telomerase activity is
a useful test for cancer prognosis and manage-
ment since it is repressed in almost all normal
cells and reactivated in immortal cells and
many tumor tissues (1). In an effort to better
understand the prognostic value of telomerase
measurement, new approaches have been pro-
posed. The telomeric repeat amplification pro-
tocol (TRAP) assay is considered to be the
gold standard. It is performed in a single tube
reaction, where the telomerase first synthe-
sizes extension products which work as tem-
plates for subsequent amplification by the poly-
merase chain reaction (PCR). However, the
detection of TRAP products involves either
radioactive end-labeling of a telomerase primer
with [g-32P]ATP or DNA staining agents such
as SYBR green (1,2).
In order to avoid the use of radioactive
products or the need for costly laboratory
equipment and reagents, we describe herein
a simple, low cost and rapid TRAP assay,
which, in addition, has higher sensitivity and
requires a shorter processing time when com-
pared with previously described methods (3).
As an example of sensitivity and protocol
optimization for the detection of telomerase
activity, we analyzed extracts prepared from
thyroid carcinoma cell lines and fresh tissue
from samples obtained from patients at Uni-
versidade Federal de Sªo Paulo, Sªo Paulo,
SP, Brazil. We analyzed specimens from 21
thyroid tumors (2 normal tissue samples, 10
papillary thyroid carcinomas, 6 follicular thy-
roid carcinomas and 3 undifferentiated thy-
roid carcinomas), 1 thyroid papillary carci-
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noma cell line (NPA) (4), 1 thyroid follicular
thyroid cell line (WRO) (5), 1 undifferenti-
ated thyroid carcinoma cell line (ARO) (4), 3
adjacent normal thyroid tissues, 2 samples
from benign thyroid disease, and 27 bone
marrow aspirates from 14 patients with acute
lymphocytic leukemia, 9 with acute myelo-
cytic leukemia, 3 with chronic myelocytic
leukemia, and 1 with myelodysplastic syn-
drome. The samples obtained from thyroid
tissues were rapidly frozen and stored at
-80”C until the time for the TRAP assay. The
bone marrow aspirates were frozen in RPMI
1640 medium (Life Technologiesâ, Rock-
ville, MD, USA) with 5% dimethylsulfoxide
and stored at -80”C (6). The cell lines were
grown in Dulbeccos modified Eagles me-
dium containing 10% fetal calf serum (4,5).
We used an extract obtained from ARO
and NPA cell lines inactivated by heating at
85”C for 10 min as a negative control. We
demonstrated the absence of primer-dimer
and PCR contamination by adding 2 µl 1X
CHAPS (3-[(3-cholamidopropyl)dimethyl-
ammonio]-1-propane-sulfonate) lysis buffer
to the reaction mixture instead of 2 µl of
extracts. Quantification controls were per-
formed by adding 1 and 2 µl of TSR8 (pro-
vided by the TRAPeze kit, Oncor, Inc., Gai-
thersburg, MD, USA) to the reaction mix-
ture.
Telomerase activity was determined us-
ing the TRAPeze kit which is based on an
improved version of the original method
described by Kim et al. (1). Ten to 50 mg of
frozen tissue were placed in a sterile mortar,
powdered by crushing with a matching pestle,
transferred to a sterile 1.5-µl microcentri-
fuge tube and resuspended in 200 µl of 1X
CHAPS lysis buffer (10 mM Tris-HCl, pH
7.5, 1 mM MgCl2, 1 mM EGTA, 0.1 mM
benzamidine, 5 mM mercaptoethanol, 0.5%
CHAPS, and 10% glycerol). To avoid the
problems most commonly occurring in the
TRAP assay, 20 U of the RNAse inhibitor,
0.4 M dithiothreitol (DTT), was always added
to the extract and RNAse-free tips, tubes and
solutions were used. The samples from bone
marrow aspirates were thawed and centri-
fuged at 1,250 rpm for 5 min; the supernatant
was discarded and the pellet was resuspended
in 200 µl 1X CHAPS lysis buffer, 20 U
RNAse inhibitor, and 0.4 M DTT. After the
samples were homogenized in 1X CHAPS,
the suspension was incubated on ice for 30
min, shaken at 5-min intervals and then cen-
trifuged at 14,000 g for 20 min at 4”C. The
supernatant was transferred to a sterile tube
and protein concentration was determined in
all extracts (TRAPeze telomerase detection
kit). Two micrograms of protein was used
for the tissue sample and 1 µg for the bone
marrow aspirate, as recommended by the
TRAPeze telomerase detection kit.
Since the cell lines were used to deter-
mine the sensitivity of the silver-staining
method, the cell number was first counted
using a Neubauer chamber (7) and then cen-
trifuged. The extract was then resuspended
in 200 µl 1X CHAPS lysis buffer. Thus, a
certain amount of protein from the ARO and
NPA telomerase-positive cell lines, which
corresponded to 5000, 2500, 1000, 500, 100,
30, and 10 cells, was used.
When telomerase was present in the ex-
tracts, it added a number of telomeric repeats
to the 3’ end of a substrate oligonucleotide
telomerase primer (5’-ATTCCGTCGAGCA
GAGTT-3’). Telomerase was elongated for
30 min at 37”C. The extended products were
then amplified by PCR using a telomerase
primer and a reverse primer. In addition,
each reaction mixture contained a primer
(K1) and a template (TSK1) for amplifica-
tion of a 36-bp internal standard. The reac-
tion was subjected to 30 cycles at 94”C for
30 s and 60”C for 30 s. Both elongation and
PCR were performed in the same tube con-
taining the cell extract with 20 mM Tris-
HCl, pH 8.3, 1.5 mM MgCl2, 63 mM KCl,
0.05% Tween 20, 10 mM EGTA, 0.5 mg
BSA, 50 µM each dNTPs, 2 U Taq poly-
merase (Life Technologiesâ), and 0.1 µg of
each primer in a final volume of 50 µl.
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Five microliters of a buffer containing
0.25% bromophenol blue, 0.25% xylenocy-
anol and 50% glycerol was added to each
PCR product. Twenty-five microliters of each
sample and controls were loaded onto a
12.5% non-denaturing polyacrylamide gel
in 0.5X TBE buffer (1.5 mm spacer and 15 x
17 cm vertical gel, Life Technologiesâ). Elec-
trophoresis was carried out at 150 V in 0.5X
TBE buffer at room temperature until the
bromophenol blue just ran off the gel. The
gel was transferred to a fixing solution con-
taining 0.5% acetic acid and 10% ethanol
with gentle shaking for 15 min. After addi-
tion of 0.2% AgNO2, the gel was stained for
10 min followed by washing twice in dis-
tilled water and then incubated in develop-
ing solution (0.1% formaldehyde and 3%
NaOH) for about 10 min (8). The gel was
handled after staining, maintained wet and
photographed on 677 Polaroid film.
Telomerase activity was considered posi-
tive when a ladder of products was observed
starting at 50 bp, with 6-bp increments. A 36-
bp internal positive control band was detected
in every line and was used to identify the non-
informative specimen inhibitors of Taq DNA
polymerase. Conversely, if the extract was
telomerase negative, only the 36-bp internal
control was observed. The results revealed
that telomerase activity can be detected in
extracts from 5,000 to as few as 10 cells;
however, different intensities of the telomer-
ase ladder were observed (Figure 1). Telomer-
ase activity was also detected in 6/10 NPA, 3/
6 WRO, 2/3 ARO, 3/3 thyroid cell lines, and in
all leukemia samples (Figure 2). Telomerase
activity was not present in ARO and NPA cell
lines after heat inactivation. The samples and
controls were analyzed at least twice and fresh
material was used each time. Telomerase ac-
tivity was preserved in the positive extracts
stored at -80”C for several months when a new
assay was performed.
Recent studies have demonstrated that
most normal human somatic cells exhibit
undetectable levels of telomerase activity,
Figure 1. Detection of telomerase activity by the silver-staining method in a
papillary thyroid carcinoma cell line (NPA) and in a follicular thyroid carcinoma
cell line (ARO). Lanes 1-7, ARO cell line; lanes 8-14, NPA. Telomerase activity
was detected in extracts from 5,000 cells (lanes 1, 8), 2,500 cells (lanes 2, 9),
1,000 cells (lanes 3, 10), 500 cells (lanes 4, 11), 100 cells (lanes 5, 12), 30 cells
(lanes 6, 13), 10 cells (lanes 7, 14), in the primer-dimer control (lane 15) and
TSR8 control (lane 16), and in ARO cells inactivated by heating (lane 17) (15.4 x
9.8 cm; 1:100).
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whereas the majority of tumor cells express
telomerase (3). Telomerase activity is asso-
ciated with continued proliferation and im-
mortalization, characterizing the advance of
Figure 2. Detection of telomerase activity by the silver-staining method in
papillary thyroid carcinomas (NPA), follicular thyroid carcinomas (WRO), undif-
ferentiated thyroid carcinomas (ARO), and all leukemia samples. NPA cell line
(lane 20); WRO cell line (lane 19); undifferentiated thyroid carcinoma (lanes 17,
18); mixed thyroid carcinoma (lane 16); mixed thyroid carcinoma (papillary/
medullar thyroid carcinoma) (lane 15); papillary thyroid carcinoma (lanes 4, 5,
14); TSR8 control (lanes 12, 13); primer-dimer control (lane 11); mixed thyroid
carcinoma (follicular/medullar thyroid carcinoma) (lane 10); normal control (lanes
7, 9); Goiter (lane 8); follicular thyroid carcinoma (lanes 1, 3, 6); lymph node
metastases from papillary thyroid carcinoma (lane 2) (9.8 x 4.6 cm; 1:100).
2 3 4 5 6 7 8 9 10 11 12 13 14 15 161 17
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tumor cells to immortality and their potential
for malignancy (9). In addition, many stud-
ies have investigated the correlation between
telomerase activity and clinical-pathological
factors such as tumor size, histopathological
grade, stage, clinical outcome and genetic
alterations (10,11). These studies found that
an increase in telomerase activity may be
associated with tumor progression and that
its level may be of prognostic value. Thus,
the TRAP assay has become an important
additional procedure for the identification of
a marker associated with the acquisition of
immortality and malignancy. However, a
common problem in many laboratories is the
equipment and reagents required to detect
telomerase activity. Since the isotopic label-
ing for the TRAP assay is not a common
routine procedure, we have developed a
highly sensitive method to detect telomerase
activity by a non-isotopic silver-staining
method. Even though an instrument for de-
tecting telomerase activity is available, this
procedure is less sensitive and quite differ-
ent from ours. We are able to detect telomer-
ase activity in an extract with as few as 10
cells while the alternative method mentioned
requires 1,000 cells (3). Presumably, our
optimized protocol allowed the detection of
increased band intensity. We used different
pre-staining times and solutions, decreased
staining time with a higher concentration of
silver nitrate in the staining solution, and
different developing solutions and times.
Since it can detect telomerase activity in
a very small number of cells, the procedure
could be helpful for the analysis of anything
from extremely small samples obtained by
minimally invasive fine-needle aspiration to
surgical biopsies and specimens. The availa-
bility of this technique may help in the char-
acterization of tumor tissues to reveal the
character of the phenotype, which is clini-
cally very valuable. The methodology de-
scribed here is a procedure of very high
sensitivity that reduces exposure to radioac-
tivity, requires minimal equipment and can
be used immediately in many laboratories.
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